• Something wrong with this record ?

Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors

M. Kubczak, A. Szustka, JZ. Błoński, T. Gucký, M. Misiewicz, V. Krystof, P. Robak, M. Rogalińska,

. 2019 ; 19 (5) : 3593-3603. [pub] 20190305

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19034720

Chronic lymphocytic leukemia (CLL) treatment is improving; however, some patients do not respond to therapy. Due to the high heterogeneity in disease development, there is an urgent need for personalization of therapy. In the present study, the response of leukemic mononuclear cells to anticancer drugs used for CLL treatment (cladribine + mafosfamide; CM or CM combined with rituximab; RCM) was compared with the response to new cyclin‑dependent kinase (CDK) inhibitors: BP14 and BP30. Viable apoptotic and necrotic cells were quantified by flow cytometry using propidium iodide and Yo‑Pro stains. CDK inhibitors were studied in several doses to determine the reduction of necrosis and simultaneous increase of apoptosis in leukemic cell incubations with anticancer agents. The distinct cell response to applied doses/anticancer agents was observed. Results obtained in the current manuscript confirmed that modulation of doses is important. This was particularly indicated in results obtained at 24 h of cells incubation with anticancer agent. While an important time for analysis of anticancer response efficacy (monitoring of apoptosis induction potential) seems to be 48 h of cells exposition to anticancer agents. High variability in response to the drugs revealed that both the nature and the dose of the anticancer agents could be important in the final effect of the therapy. The present findings support the thesis that personalized medicine, before drug administration in the clinic, could be important to avoid the application of ineffective therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034720
003      
CZ-PrNML
005      
20211207131725.0
007      
ta
008      
191007s2019 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/mmr.2019.10007 $2 doi
035    __
$a (PubMed)30864706
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kubczak, Małgorzata $u Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90‑236 Lodz, Poland.
245    10
$a Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors / $c M. Kubczak, A. Szustka, JZ. Błoński, T. Gucký, M. Misiewicz, V. Krystof, P. Robak, M. Rogalińska,
520    9_
$a Chronic lymphocytic leukemia (CLL) treatment is improving; however, some patients do not respond to therapy. Due to the high heterogeneity in disease development, there is an urgent need for personalization of therapy. In the present study, the response of leukemic mononuclear cells to anticancer drugs used for CLL treatment (cladribine + mafosfamide; CM or CM combined with rituximab; RCM) was compared with the response to new cyclin‑dependent kinase (CDK) inhibitors: BP14 and BP30. Viable apoptotic and necrotic cells were quantified by flow cytometry using propidium iodide and Yo‑Pro stains. CDK inhibitors were studied in several doses to determine the reduction of necrosis and simultaneous increase of apoptosis in leukemic cell incubations with anticancer agents. The distinct cell response to applied doses/anticancer agents was observed. Results obtained in the current manuscript confirmed that modulation of doses is important. This was particularly indicated in results obtained at 24 h of cells incubation with anticancer agent. While an important time for analysis of anticancer response efficacy (monitoring of apoptosis induction potential) seems to be 48 h of cells exposition to anticancer agents. High variability in response to the drugs revealed that both the nature and the dose of the anticancer agents could be important in the final effect of the therapy. The present findings support the thesis that personalized medicine, before drug administration in the clinic, could be important to avoid the application of ineffective therapy.
650    _2
$a protinádorové látky $x aplikace a dávkování $x farmakologie $7 D000970
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cyklin-dependentní kinasy $x antagonisté a inhibitory $7 D018844
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x farmakoterapie $x metabolismus $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a inhibitory proteinkinas $x aplikace a dávkování $x farmakologie $7 D047428
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
700    1_
$a Szustka, Aleksandra $u Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90‑236 Lodz, Poland.
700    1_
$a Błoński, Jerzy Z $u Department of Hematology, Medical University of Lodz, 93‑510 Lodz, Poland.
700    1_
$a Gucký, Tomáš, $u Department of Chemical Biology and Genetics, Centre of the Region Haná for Biotechnological and Agricultural Research, Faculty of Science, Palacký University, 78371 Olomouc, Czech Republic. $d 1978- $7 ola2005284374
700    1_
$a Misiewicz, Małgorzata $u Department of Hematology, Medical University of Lodz, 93‑510 Lodz, Poland.
700    1_
$a Krystof, Vladmir $u Laboratory of Growth Regulators, Faculty of Science, Palacký University and Institute of Experimental Botany AS CR, 78371 Olomouc, Czech Republic.
700    1_
$a Robak, Paweł $u Department of Experimental Hematology, Medical University of Lodz, 93‑510 Lodz, Poland.
700    1_
$a Rogalińska, Małgorzata $u Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90‑236 Lodz, Poland.
773    0_
$w MED00181650 $t Molecular medicine reports $x 1791-3004 $g Roč. 19, č. 5 (2019), s. 3593-3603
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30864706 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20211207131723 $b ABA008
999    __
$a ok $b bmc $g 1451380 $s 1073270
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 19 $c 5 $d 3593-3603 $e 20190305 $i 1791-3004 $m Molecular medicine reports $n Mol Med Rep $x MED00181650
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Archiving options